News
SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback